Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

The gas xenon, like the other noble, or inert, gases, is known for doing very little. The class of elements, because of its ...

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

As the American population ages, a new study finds the average lifetime risk of dementia for adults over 55 is around 42 ...

Most treatments being pursued today to protect against Alzheimer’s disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research from Mass General Brigham and ...

More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

A new study found that dementia cases in the United States are projected to double from more than 500,000 in 2020 to about 1 million by 2050.